Results 61 to 70 of about 9,615 (165)
Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
Medicina, 2023 Background and Objectives: The treatment of chronic lymphocytic leukemia (CLL) has acquired new targeted therapies. In clinical trials, ibrutinib improved outcomes safely. Real-world data called for a reappraisal of ibrutinib strategies.Ana-Maria Moldovianu, Razvan Stoia, Mariana Vasilica, Iulia Ursuleac, Sorina Nicoleta Badelita, Andra Alina Tomescu, Oana Diana Preda, Alexandru Bardas, Mihaela Cirstea, Daniel Coriu +9 moredoaj +1 more sourceClinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT
Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio +6 morewiley +1 more sourceIbrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
, 2019 The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the ...Schaap, Nicolaas, Russo, D., Bethge, W., Montoto, Silvia, Browne, P., William Krüger, Passweg, J, Michel van Gelder, Gelder, M, Wulf, G., Johannes Schetelig, Koster, L, Michallet, M, Boumendil, A, Durakovic, N., Russo, D, Schaap, N.P., Scheid, C, Schoemans, Hélène, Fox, CP, Russo, Domenico, Peter Dreger, Corradini, P, Corradini, P., Schoemans, H., Durakovic, Nadira, Montoto, S, Fox, Christopher P, Bethge, W, Muller, Lutz, Schetelig, J., Paul Browne, Gerald Wulf, Jan Cornelissen, Silvia Montoto, Nicolaas Schaap, Jennifer Hoek, Linda Koster, Hoek, J, Mauricette Michallet, Ariane Boumendil, Christof Scheid, van Gelder, Michel, Cornelissen, J, Schetelig, Johannes, Michallet, Mauricette, Mohamad Sobh, Browne, Paul, Kruger, W., Hoek, Jennifer, Nadira Durakovic, Lutz Muller, Krueger, William, Boumendil, Ariane, Bethge, Wolfgang, Fox, Christopher P., Durakovic, N, Schetelig, J, Kroger, N., Jakob Passweg, Krüger, William, Montoto, S., Wulf, Gerald, Wulf, G, Schaap, N, Scheid, C., Krüger, W, Dreger, Peter, Christopher P. Fox, Sobh, Mohamad, Paolo Corradini, Passweg, Jakob, Domenico Russo, Kroger, N, Hélène Schoemans, Boumendil, A., Browne, P, Dreger, P., Koster, Linda, Sobh, M., Nicolaus Kroger, Muller, L, Kroger, Nicolaus, Corradini, Paolo, Michallet, M., Passweg, J., Dreger, P, Sobh, M, Fox, C.P., Muller, L., Cornelissen, Jan, Gelder, M. van, Scheid, Christof, Wolfgang Bethge, Schoemans, H, Russo D, van Gelder M, Wulf G, Krüger W, Kroger N., Russo D., Koster L., Scheid C, Durakovic N., Montoto S., Scheid C., Sobh M., Michallet M., Kruger W., Boumendil A, Schoemans H., Cornelissen J., van Gelder M., Koster L, Schetelig J., Kroger N, Michallet M, Schaap N, Muller L, Sobh M, Browne P., Fox C. P., Bethge W, Bethge W., Passweg J, Schetelig J, Cornelissen J, Dreger P., Schaap N., Fox CP, Montoto S, Browne P, Muller L., Corradini P., Durakovic N, Corradini P, Schoemans H, Hoek J, Dreger P, Wulf G., Boumendil A., Passweg J., Hoek J. +142 morecore +2 more sourcesIn‐frame variants in TP53 gene identified in adult leukemia samples are predominantly deleterious: a study of the TP53 Network of Education and Research Initiative on CLL
The Journal of Pathology, EarlyView.Abstract
The prognostic and predictive impact of TP53 variants in leukemia led to their inclusion in diagnostic and treatment guidelines, increasing the demand for rapid, reliable laboratory analysis, interpretation, and reporting. While most TP53 variants identified in tumor samples can be interpreted using data from large‐scale functional studies ...Šárka Pavlová, Johana Gombíková, Silvia Petrezsélyová, Libor Macůrek, Marcela Ženatová, Marie Zádrapová, Anna Panovská, Eva Zapletalová, Blanca Ferrer Lores, Alicia Serrano Alcalá, Eugen Tausch, Stephan Stilgenbauer, Fanny Baran‐Marszak, Gregory Lazarian, Miguel Alcoceba, Ana Balanzategui, Lisa Bonello, Ivana Ježíšková, Martina Sopkovičová, Silvia Zibellini, Marzia Varettoni, Audrey Bidet, Helena Podgornik, Sandra Šućurović, Riccardo Moia, Mónica López‐Guerra, Mark Catherwood, Šárka Pospíšilová, Jitka Malčíková +28 morewiley +1 more sourceInhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Haematologica, 2018 Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson +14 moredoaj +1 more sourceIbrutinib: a paradigm shift in management of CLL [PDF]
, 2014 B-cell receptor (BCR) signaling plays a vital role in B-cell malignancies; Bruton tyrosine kinase is a critical mediator of this signaling. BCR signaling, either constitutively or following antigen binding, leads to activation of several downstream ...Burger, Jan A, O’Brien, Susan, Wierda, William G, Badar, Talha +3 morecore +1 more sourceSAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma
British Journal of Haematology, EarlyView.Summary
The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad +25 morewiley +1 more sourceLenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups
British Journal of Haematology, EarlyView.Summary
Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb +45 morewiley +1 more source